Site-specific68 Ga-labeled Annexin A5 as a PET imaging agent for apoptosis

Abstract Purpose Two variants of Annexin A5 (Cys2-AnxA5 and Cys165-AnxA5) were labelled with Gallium-68 in order to evaluate their biological properties. Procedures Biodistribution and pharmacokinetics of the radiotracers were studied with μPET in healthy mice and in a mouse model of hepatic apoptos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nuclear medicine and biology 2011, Vol.38 (3), p.381-392
Hauptverfasser: Bauwens, Matthias, De Saint-Hubert, Marijke, Devos, Ellen, Deckers, Niko, Reutelingsperger, Chris, Mortelmans, Luc, Himmelreich, Uwe, Mottaghy, Felix M, Verbruggen, Alfons
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Purpose Two variants of Annexin A5 (Cys2-AnxA5 and Cys165-AnxA5) were labelled with Gallium-68 in order to evaluate their biological properties. Procedures Biodistribution and pharmacokinetics of the radiotracers were studied with μPET in healthy mice and in a mouse model of hepatic apoptosis. μPET imaging after IV injection of the tracers in combination with μMRI was performed in Daudi tumor bearing mice before and after treatment with a combination of chemotherapy and radiotherapy. Results The biodistribution data indicated a fast urinary clearance with only minor hepatobilliary clearance, although a high retention in the kidneys was observed. Animals treated with anti-Fas showed a 3 to 8 times higher liver uptake as compared to healthy animals. Tumor uptake of68 Ga-Cys2-AnxA5 and68 Ga-Cys165-AnxA5 was low but significantly increased after therapy. Conclusion Both68 Ga-Cys2-AnxA5 and68 Ga-Cys165-AnxA5 show a clear binding to apoptotic cells and are promising tracers for rapid evaluation of cancer therapy.
ISSN:0969-8051
DOI:10.1016/j.nucmedbio.2010.09.008